Marshall Wace’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Marshall Wace’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-34,811	Closed	-$592K	–	3061
2020 Q4	$592K	Buy	+34,811	New	+$436K	﹤0.01%	1405
2019 Q4	–	Sell	-286,782	Closed	-$1.11M	–	2222
2019 Q3	$1.11M	Sell	286,782 -60,561	-17%	-$332K	0.01%	923
2019 Q2	$2.09M	Buy	+347,343	New	+$3.32M	0.02%	757
2018 Q2	–	Sell	-15,000	Closed	-$258K	–	894
2018 Q1	$258K	Buy	+15,000	New	+$293K	0.01%	490
2016 Q1	–	Sell	-237,141	Closed	-$9.84M	–	1249
2015 Q4	$9.84M	Buy	237,141 +71,262	+43%	+$2.39M	0.09%	228
2015 Q3	$2.55M	Buy	+165,879	New	+$3.56M	0.03%	406

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Marshall Wace's FPRX Position: Q1 2021 in Review

Marshall Wace sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 34,811 shares — an estimated $592K sold.

Marshall Wace first reported a position in FPRX in Q3 2015 and held it in 6 quarters. The position peaked at $9.84M in Q4 2015. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

Marshall Wace reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
Marshall Wace sold 34,811 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $592K.
Marshall Wace first reported a position in Five Prime Therapeutics, Inc. in Q3 2015 and held it in 6 quarters.
Marshall Wace's Five Prime Therapeutics, Inc. position peaked at $9.84M in Q4 2015.
147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Marshall Wace's 13F filing for Q1 2021, filed 17 May 2021.